2,871 results on '"Stilgenbauer, Stephan"'
Search Results
2. The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma—a randomized, open-label phase III trial of the European mantle cell lymphoma network
3. Venetoclax resistance in acute lymphoblastic leukemia is characterized by increased mitochondrial activity and can be overcome by co-targeting oxidative phosphorylation
4. SOP – Darmpassagestörung in der Palliativmedizin
5. Tislelizumab plus zanubrutinib for Richter transformation: the phase 2 RT1 trial
6. Evolutionary history of transformation from chronic lymphocytic leukemia to Richter syndrome
7. Molecular map of chronic lymphocytic leukemia and its impact on outcome
8. T-bet suppresses proliferation of malignant B cells in chronic lymphocytic leukemia
9. Acalabrutinib, venetoclax, and obinutuzumab in relapsed/refractory CLL: final efficacy and ctDNA analysis of the CLL2-BAAG trial
10. Reassessing the chronic lymphocytic leukemia International Prognostic Index in the era of targeted therapies
11. First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial
12. Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network
13. Six-year follow-up and subgroup analyses of a phase 2 trial of venetoclax for del(17p) chronic lymphocytic leukemia
14. Author Correction: Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia
15. Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia
16. Molecular characterization of Richter syndrome identifies de novo diffuse large B-cell lymphomas with poor prognosis
17. Loss of ORP3 induces aneuploidy and promotes bladder cancer cell invasion through deregulated microtubule and actin dynamics
18. Profile of the multicenter cohort of the German Cancer Consortium’s Clinical Communication Platform
19. Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study
20. Activation of Notch and Myc signaling via B cell-restricted depletion of Dnmt3a generates a consistent murine model of chronic lymphocytic leukemia
21. Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial
22. Cancer care in German centers of excellence during the first 2 years of the COVID-19 pandemic
23. Results of VOICE: a global survey of disease-specific knowledge and perspectives of real-world patients with CLL
24. Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/TP53mut
25. Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial
26. High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations
27. Oncogenic role and target properties of the lysine-specific demethylase KDM1A in chronic lymphocytic leukemia
28. Kapazität der onkologischen Versorgung in deutschen onkologischen Spitzenzentren während der ersten 2 Jahre der COVID-19-Pandemie
29. The impact of complex karyotype on the overall survival of patients with relapsed chronic lymphocytic leukemia treated with idelalisib plus rituximab
30. The proto-oncogene TCL1A deregulates cell cycle and genomic stability in CLL
31. Sequential treatment with bendamustine, obinutuzumab (GA101) and Ibrutinib in chronic lymphocytic leukemia (CLL): final results of the CLL2-BIG trial
32. Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial
33. The scaffold protein NEDD9 is necessary for leukemia-cell migration and disease progression in a mouse model of chronic lymphocytic leukemia
34. Obinutuzumab, acalabrutinib, and venetoclax, after an optional debulking with bendamustine in relapsed or refractory chronic lymphocytic leukaemia (CLL2-BAAG): a multicentre, open-label, phase 2 trial
35. Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia.
36. Longitudinal analyses of CLL in mice identify leukemia-related clonal changes including a Myc gain predicting poor outcome in patients
37. Proteogenomics refines the molecular classification of chronic lymphocytic leukemia
38. Viral transduction of primary human lymphoma B cells reveals mechanisms of NOTCH-mediated immune escape
39. Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemia
40. Evaluation of vecabrutinib as a model for noncovalent BTK/ITK inhibition for treatment of chronic lymphocytic leukemia
41. KIR2DS1–HLA-C status as a predictive marker for benefit from rituximab: a post-hoc analysis of the RICOVER-60 and CLL8 trials
42. The CLL12 trial: ibrutinib vs placebo in treatment-naïve, early-stage chronic lymphocytic leukemia
43. Infections in patients with chronic lymphocytic leukemia treated with time limited targeted drug combinations.
44. Fludarabine, cyclophosphamide, and rituximab as first‐line treatment in patients with chronic lymphocytic leukemia: A long‐term analysis of the German CLL Study Group (GCLLSG) registry.
45. Impairment of α-tubulin and F-actin interactions of GJB3 induces aneuploidy in urothelial cells and promotes bladder cancer cell invasion.
46. EOMES is essential for antitumor activity of CD8+ T cells in chronic lymphocytic leukemia
47. Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations
48. FDG PET/CT to detect bone marrow involvement in the initial staging of patients with aggressive non-Hodgkin lymphoma: results from the prospective, multicenter PETAL and OPTIMAL>60 trials
49. Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials
50. Abstract P15: Cross-species DNA methylation profiling of T and B cell populations in T-PLL and B-CLL compared to TCL1 transgenic mouse models
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.